Medexus Pharmaceuticals Inc.

WHO'M
ai
Digital Profiler. Einfach den AI-Button klicken
CUSIP
58410Q203
SEDOL
N/A
CIK
N/A
www.medexus.com
LEI:
©
FIGI: BBG0029BPQV2
MDP
Medexus Pharmaceuticals Inc.
GICS: - · Sektor: EQTY · Sub-Sektor: Drug Manufacturers—Specialty & Generic
AI
PROFILER
NAME
Medexus Pharmaceuticals Inc.
ISIN
CA58410Q2036
TICKER
MDP
MIC
XTSE
REUTERS
MDP.TO
BLOOMBERG
MDP CN
BUILD THEMEFOLIO IDEEN TEILEN DISKUTIEREN
HEBEL INVESTIEREN
Financial Intelligence
360° iHub Crowd ATH Tracker Index Tracker ETF TF Spicy X-Billboard
FÜR INVESTOREN
FÜR TRADER
Börsenhandel Warrants
Der X-News Explorer ist die ultimative Informationsquelle für börsenaffine Anleger, die sich schnell und komfortabel einen Überblick über die aktuelle Nachrichtenlage eines börsennotierten Unternehmens verschaffen möchten. Ihnen stehen hier verschiedene Newswire-Services zur Verfügung. Wird ein News-Alert angezeigt, liegen Unternehmensnachrichten vor, die Sie möglicherweise interessieren könnten. Dieser Service wird Ihnen von Newsfile Corp. bereitgestellt.
Fr., 14.03.2025       Medexus Pharmaceuticals
CA58410Q2036

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - March 14, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) recently completed an agreement with NX Development Corp., the licensor of Medexus's rights to Gleolan® in the United States, to terminate the license, supply, and distribution agreement between the parties and return r...
Zur Nachricht
Medexus Pharmaceuticals
Technische Analyse Termsheet Terminal
Permalink
Mo., 24.02.2025       Medexus Pharmaceuticals
CA58410Q2036

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - February 24, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to announce that GRAFAPEX™ (treosulfan) for Injection is now commercially available in the United States."We are pleased to report this positive development, which marks a strategically important step for...
Zur Nachricht
Medexus Pharmaceuticals
Technische Analyse Termsheet Terminal
Permalink
Mi., 05.02.2025       Medexus Pharmaceuticals
CA58410Q2036

Fiscal Q3 2025 revenue of $30.0 million, net income of $0.7 million, operating income of $3.8 million, and Adjusted EBITDA* of $5.8 millionManagement to host conference call at 8:00 AM Eastern time on Thursday, February 6, 2024Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - February 5, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: ME...
Zur Nachricht
Medexus Pharmaceuticals
Technische Analyse Termsheet Terminal
Permalink
Di., 04.02.2025       Medexus Pharmaceuticals
CA58410Q2036

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - February 4, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) recently completed listing agreements with Ontario's Ministry of Health (Ontario Public Drug Programs) and Ontario Health (Cancer Care Ontario) for Trecondyv® (treosulfan for injection). The Ontario Public Drug Progra...
Zur Nachricht
Medexus Pharmaceuticals
Technische Analyse Termsheet Terminal
Permalink
Fr., 31.01.2025       Medexus Pharmaceuticals
CA58410Q2036

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - January 31, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Thursday, February 6, 2025 to discuss Medexus's results for its third fiscal quarter ended December 31, 2024. Medexus expects to file its financial statements and ...
Zur Nachricht
Medexus Pharmaceuticals
Technische Analyse Termsheet Terminal
Permalink
Fr., 31.01.2025       Medexus Pharmaceuticals
CA58410Q2036

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - January 31, 2025) - Medexus Pharmaceuticals Inc. (TSX: MDP) ("Medexus" or the "Company"), is pleased to announce the closing of its previously announced overnight marketed underwritten offering (the "Offering") of 7,500,000 common shares of the Company (the "Common Shares") at a public offe...
Zur Nachricht
Medexus Pharmaceuticals
Technische Analyse Termsheet Terminal
Permalink
Mi., 22.01.2025       Medexus Pharmaceuticals
CA58410Q2036

Medexus will target a commercial launch in 1H CY2025; potential for annual product-level revenue to exceed US$100 million within five years after commercial launchToronto, Ontario and Chicago, Illinois--(Newsfile Corp. - January 22, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to provide a business update regarding the succe...
Zur Nachricht
Medexus Pharmaceuticals
Technische Analyse Termsheet Terminal
Permalink
Mi., 15.01.2025       Medexus Pharmaceuticals
CA58410Q2036

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - January 15, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) recently completed a listing agreement with British Columbia's Provincial Health Services Authority (PHSA), a publicly funded health service provider in the Canadian province, for a new approved indication for Trecondyv...
Zur Nachricht
Medexus Pharmaceuticals
Technische Analyse Termsheet Terminal
Permalink
Mi., 07.02.2024       Medexus Pharmaceuticals
CA58410Q2036

Fiscal Q3 2024 revenue of $25.2 million, Operating income of $1.6 million, and Adjusted EBITDA* of $3.2 millionManagement to host conference call at 8:00 AM Eastern time on Thursday, February 8, 2024Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - February 7, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today announced its ope...
Zur Nachricht
Medexus Pharmaceuticals
Technische Analyse Termsheet Terminal
Permalink
Di., 30.01.2024       Medexus Pharmaceuticals
CA58410Q2036

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - January 30, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Thursday, February 8, 2024 to discuss Medexus's results for its third fiscal quarter ended December 31, 2023. Medexus expects to file its financial statements and ...
Zur Nachricht
Medexus Pharmaceuticals
Technische Analyse Termsheet Terminal
Permalink
We are different
OPEN FINANCIAL
DATA & KNOWLEDGE HUB
We make the difference
Informationen zu Product Placements

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S